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fits with regard to long-term results in patients with
FH. Comparing single and double ITAs by means of
multivariate analysis, Naunheim and colleagues18
reported that double ITA grafting was not protective
over a 15-year period with regard to survival. Sergeant
and colleagues19 examined whether extensive arterial
grafting beyond a single graft reduced the prevalence
and consequences of myocardial infarction after
CABG in a large series of 9600 patients. Multivariable
analysis showed that arterial grafting lowered the
prevalence of periprocedural, intermediate term, and
late infarction. Although arterial grafting improved the
10-year survival, no additional benefit or cost of
extensive arterial grafting was identified. Lytle and
colleagues20 conducted a long-term (mean follow-up
interval of 10 years) study of patients undergoing
CABG who received either single (8123 patients) or
bilateral ITA grafts (2001 patients). Patients who
received 2 ITA grafts had significantly decreased risks
of death, reoperation, and percutaneous transluminal
coronary angioplasty. Patients with FH in the present
study were relatively young, with a mean age of 55
years. In addition, coronary atherosclerosis in patients
with FH progresses more rapidly than that in the gen-
eral population. We think that intensive cholesterol-
lowering therapies are mandatory for patients with
FH, even in the case of total arterial grafting. Further
follow-up is warranted to determine more accurately
whether multiple arterial grafting is preferable to sin-
gle arterial grafting in patients with FH.
In conclusion, in patients with heterozygous FH, ITA
grafting increased the long-term freedom from reoper-
ation compared with saphenous vein grafting. No addi-
tional benefits of multiple arterial grafting could be
identified.
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Commentary
We compliment Kawasuji and associates on their
management and results over 18 years in 101 patients
with familial hypercholesterolemia and severe coro-
nary artery disease. Seventy patients received one or
more arterial bypass grafts and 30 patients have saphe-
nous vein grafts, for an average of 2.6 grafts per
patient. Postoperatively, the patients’ cholesterol levels
were reduced to less than 180 mg/dL and their low-den-
sity lipoprotein cholesterol levels were reduced to less
than 130 mg/dL with diet therapy and cholesterol-low-
ering drugs. The 13 patients who did not respond to
drug therapy were treated with low-density lipoprotein
apheresis.
This group of patients has premature coronary artery
disease combined with high cholesterol levels and pro-
vides an excellent model to evaluate therapies to opti-
mize results in high-risk patients. Postoperative man-
agement of patients can have an influence on the
incidence of reoperation, and the importance of aggres-
sive control of cholesterol levels should not be ignored.
Aggressive lowering of low-density lipoprotein choles-
terol levels was shown to decrease obstructive changes
in saphenous vein grafts by 31% according to the
National Heart, Lung, and Blood Institute study.1
The effect of maintaining low cholesterol levels in
patients with complete arterial grafting is not known.
Flaker and associates2 showed that a 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitor reduced
clinical events in revascularized postinfarction patients
with average cholesterol levels. This fact, combined
with the knowledge that control of cholesterol levels in
the postoperative period halted the development of new
lesions in native coronary arteries and bypass vein
grafts but did not reduce the progression of vein graft
lesions, has important implications.3 It seems that low-
ering of cholesterol levels is also beneficial in patients
with total arterial grafting, at least in part because of
slowing the development of new lesions. Intensive con-
trol of cholesterol levels in the postoperative period
should be started immediately to prevent the progres-
sion of disease.
Even though this study did not reveal any significant
benefit from multiple arterial grafting, one would sus-
pect that the survival and outcomes would eventually
be affected in view of the low patency in the saphenous
vein grafts. The fact that the internal thoracic artery
(ITA) has a higher patency than venous grafts supports
the importance of arterial grafts. The benefits from total
arterial revascularization will not be seen unless a very
large number of patients are observed for an extended
length of time. Lytle and associates4 reviewed more
than 10,000 patients to show a benefit from bilateral
ITA grafting.
What is not known is whether all arterial conduits are
equivalent. Patency of the ITA, but not that of the radi-
al artery, which differs in that it is a muscular artery,
has proven to be superior. Further long-term studies
into different forms of arterial revascularization will
answer these questions.
This article demonstrates the importance of using
arterial grafts combined with strict control of total and
low-density lipoprotein cholesterol levels in patients
undergoing coronary artery bypass grafting. Current
available data on the beneficial effects of the new statin
drugs only increase the importance of aggressive con-
trol of cholesterol levels in the postoperative patient. As
surgeons, we must educate our patients and their fami-
ly physicians on this vital issue. Striving for ways to
halt progression of native and bypass graft disease may
further decrease the incidence of coronary reoperations
and other morbidities and enhance patient survival.
Alfred J. Tector, MD
Monica L. McDonald, MD
Milwaukee, Wisconsin
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